0.59
+0.0086(+1.49%)
Currency In USD
| Previous Close | 0.58 |
| Open | 0.58 |
| Day High | 0.59 |
| Day Low | 0.56 |
| 52-Week High | 4.06 |
| 52-Week Low | 0.36 |
| Volume | 2.85M |
| Average Volume | 2.44M |
| Market Cap | 95.5M |
| PE | -0.51 |
| EPS | -1.15 |
| Moving Average 50 Days | 0.49 |
| Moving Average 200 Days | 1.38 |
| Change | 0.01 |
If you invested $1000 in Tenaya Therapeutics, Inc. (TNYA) since IPO date, it would be worth $38.25 as of June 21, 2025 at a share price of $0.587. Whereas If you bought $1000 worth of Tenaya Therapeutics, Inc. (TNYA) shares 3 years ago, it would be worth $98.67 as of June 21, 2025 at a share price of $0.587.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
GlobeNewswire Inc.
May 13, 2025 12:30 PM GMT
Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart DiseaseSOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
GlobeNewswire Inc.
Apr 24, 2025 6:07 PM GMT
RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients Experience High Burden of Arrhythmias and Severe Disease
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
GlobeNewswire Inc.
Mar 31, 2025 2:00 PM GMT
TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two o